- Home
- QNCX vs ARMP Comparison
QNCX vs ARMP Comparison
Compare QNCX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ARMP
- Stock Information
- Founded
- QNCX 2012
- ARMP N/A
- Country
- QNCX United States
- ARMP United States
- Employees
- QNCX N/A
- ARMP N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNCX Health Care
- ARMP Health Care
- Exchange
- QNCX Nasdaq
- ARMP Nasdaq
- Market Cap
- QNCX 92.3M
- ARMP 80.0M
- IPO Year
- QNCX 2019
- ARMP N/A
- Fundamental
- Price
- QNCX $1.60
- ARMP $2.08
- Analyst Decision
- QNCX Strong Buy
- ARMP Strong Buy
- Analyst Count
- QNCX 4
- ARMP 1
- Target Price
- QNCX $9.50
- ARMP $7.00
- AVG Volume (30 Days)
- QNCX 147.1K
- ARMP 12.0K
- Earning Date
- QNCX 11-13-2024
- ARMP 03-20-2025
- Dividend Yield
- QNCX N/A
- ARMP N/A
- EPS Growth
- QNCX N/A
- ARMP N/A
- EPS
- QNCX N/A
- ARMP N/A
- Revenue
- QNCX N/A
- ARMP $5,467,000.00
- Revenue This Year
- QNCX N/A
- ARMP $23.87
- Revenue Next Year
- QNCX N/A
- ARMP N/A
- P/E Ratio
- QNCX N/A
- ARMP N/A
- Revenue Growth
- QNCX N/A
- ARMP 34.92
- 52 Week Low
- QNCX $0.51
- ARMP $1.80
- 52 Week High
- QNCX $2.45
- ARMP $4.48
- Technical
- Relative Strength Index (RSI)
- QNCX 42.75
- ARMP 49.70
- Support Level
- QNCX $1.40
- ARMP $2.01
- Resistance Level
- QNCX $1.79
- ARMP $2.37
- Average True Range (ATR)
- QNCX 0.15
- ARMP 0.14
- MACD
- QNCX -0.02
- ARMP 0.01
- Stochastic Oscillator
- QNCX 32.79
- ARMP 30.12
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.